Nov. 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will ...

Spotlight Presentation to showcase four routes of synthesis of an approved siRNA therapeutic asset— —Joint poster presentation with Bachem to compare Codexis double-stranded RNA ligase to wild ...

DNA damage in neurons increases with chronological age and accelerates in neurodegenerative disorders, resulting in cellular and systemic dysregulation. Distinct DNA damage response strategies have ...

Synthetic biologists have embraced the design-test-build-learn (DTBL) approach from software engineering ... or chemical synthesis has enabled scientists to write custom short DNA sequences.

The session will highlight latest developments in the company’s protein homeostasis program as BPGbio continues ... Key points of the presentation include: E2 enzymes have historically been ...